Traditionally, cellular senescence has been considered a state of proliferative arrest, having cell-autonomous tumour suppressive functions in cancer and resulting in reduced tissue regenerative capacity during ageing 1 . However, increasing attention has been focused on the non-cell-autonomous activities of senescent cells on the tissue microenvironment, which occur primarily through the senescenceassociated secretory phenotype (SASP) 1 . The SASP involves a large number of secreted factors, such as cytokines, growth factors, extracellular matrix (ECM) proteins and proteases, which modulate many aspects of tumorigenesis, including immune responses, proliferative capacity, ECM integrity and vascularity 1 . Therefore, senescence is not merely tumour suppressive, but rather a complex tumour modulator, and understanding how the SASP is regulated and how it could be manipulated therapeutically is a central issue in cancer biology and other pathologies that involve disruption of tissue homeostasis. Two recent studies 2, 3 report that the mTOR kinase controls the SASP by regulating aspects of gene transcription and mRNA translation and stability. mTOR complex 1 (mTORC1) senses nutrients, growth factors and other environmental cues, and controls cell growth and proliferation by promoting anabolic metabolism 4 . Although mTORC1 has been implicated in senescence, the outcome of manipulating mTOR activity during senescence seems to vary depending on the model [5] [6] [7] [8] . Additionally, although a positive relationship between mTORC1 activity and the SASP has been suggested 6, 9 , the mechanisms for this correlation were unclear. Using the mTOR inhibitor rapamycin on human fibroblasts, Laberge et al. recently showed that the secretion of major SASP components, including the pro-inflammatory cytokine IL-6, are mTOR-dependent 2 . This was not simply due to a general reduction of protein synthesis following mTOR inhibition, as these rapamycin-sensitive SASP components were mostly modulated at the mRNA level 2 . The transcription of SASP components is largely regulated through complex positive feedback loops between pro-inflammatory cytokines and the transcription factor NF-κB, locally amplifying the pro-inflammatory cascade 10 . In the context of senescence, IL-1α (encoded by IL1A) has previously been reported as an upstream regulator of a pro-inflammatory network within the SASP through the activation of NF-κB 10 . Consistent with these observations, Laberge et al. showed that rapamycin attenuated IL-1α upregulation during senescence but, in contrast to other rapamycin-sensitive SASP components, this reduction was primarily through reduced translation. The authors proposed that mTOR facilitates IL1A translation, thereby activating NF-κB, and triggering the amplification of the downstream pro-inflammatory cytokine network through positive feedback between NF-κB and cytokines including IL-1α (Fig. 1b) .
In a separate study, Herranz et al. now provide a distinct view on mTOR's regulation of the SASP 3 . These authors identified rapamycin through a small molecule screen for SASP inhibitors, and similarly to Laberge et al. 2 , observed that following mTOR inhibition, a reduction of mRNA levels was more prominent than the effect on translation for most SASP components analysed. However, the reduction in mRNA levels seemed to be caused by enhanced mRNA degradation. They identified MAPKAPK2 (also known as MK2) as a specific target of mTOR-regulated translation during senescence. MAPKAPK2, a downstream effector of p38α MAPK, has been shown to phosphorylate the RNA-binding protein ZFP36L1 to inhibit its AU-rich element (ARE)-mediated mRNA decay (AMD) activity 11 . Herranz et al. propose that mTOR specifically promotes MAPKAPK2 translation during senescence, thereby inhibiting the AMD activity of ZFP36L1, which targets some SASP components (Fig. 1b) .
How can these two models be reconciled? Although Herranz et al. demonstrate a significant downregulation of IL1A mRNA following mTOR inhibition, they also show a preferential reduction of translation of some SASP components, including IL-1α (although IL-1α is reportedly localized at the cell surface 10 , we include it as a SASP component in a broader sense of the concept) 3 . The identity of the mRNAs encoding SASP components that are directly degraded through ZFP36L1-mediated AMD remains to be elucidated. Nevertheless, IL1A is a likely candidate, as it seems to have a relatively ARE-rich 3ʹ untranslated region (UTR) 3 . Conversely, Laberge et al. observed that IL1A mRNA levels were slightly reduced by rapamycin treatment, at least at early time points after senescence induction 2 . These results imply a potential cooperative contribution of the two mechanisms. It is notable that the two studies use different primary senescence models, with Laberge et al. focusing on DNA-damage-induced senescence and Herranz et al. studying oncogene-induced senescence (OIS). It is thus possible that the relative contributions of the two models differ between experimental systems. In addition, similarly to mTOR activity, MAPKAPK2 activation is dynamic during OIS establishment 3 , raising the possibility that the balance between these models might shift during the course of senescence. Although both studies employ several means to inhibit mTOR activity, Laberge et al. mostly use rapamycin. This allosteric inhibitor of mTORC1 partially inhibits the phosphorylation of eIF4E-binding proteins (4E-BPs), and is thus a weaker inhibitor of mTOR-mediated Cap-dependent translation initiation compared with the ATP-competitive mTOR kinase inhibitors, such as Torin1 (ref. 4) , which was the primary compound used to define the model of Herranz et al. 3 . Therefore, a systematic comparison of the effects of both inhibitor types on the differential regulation of translation during senescence would be important.
In both models, it is not entirely clear how the specificity of mTOR-dependent regulation of IL1A and MAPKAPK2 translation is achieved, as both transcripts lack the 5ʹ terminal oligopyrimidine (TOP) or TOPlike motifs that characterize the mRNAs more sensitive to mTORC1 inhibition 2, 3, 12 . Nevertheless, a recent study of genome-wide profiling of Torin1-sensitive mRNA translation in mouse embryonic fibroblasts identified Mapkapk2 as one of the most affected transcripts 12 . Interestingly, instead of the TOP(-like) motifs, Laberge et al. predicted a highly stable secondary structure downstream of the AUG in the IL1A transcript, and suggested that such structured mRNAs might be regulated by RNA helicase activity downstream of mTORC1. This idea requires experimental validation, and it would be interesting to know whether MAPKAPK2 and other mRNAs that lack TOP(-like) motifs and are sensitive to mTOR inhibition 12, 13 contain such a secondary structure.
An important and often elusive question about the in vivo SASP is whether the senescent cells are of tumour or stromal origin. Both studies show the pro-tumorigenic effects of SASP factors derived from stromal senescence (Fig. 1a(i) ) and address this question using xenograft mouse models, in which co-injected senescent fibroblasts enhance tumour development of subcutaneously injected tumour cell lines, probably through the SASP. They show that either mTOR inhibition 2, 3 or the constitutive activation of ZFP36L1 3 specifically in senescent fibroblasts blunts the enhancement of tumorigenesis. In practice, however, chemotherapy in cancer patients could cause cell death and senescence in both cancer and stromal cells, which might confound therapy effects through the tumorigenic aspect of the SASP. The present findings 2, 3 suggest that a combination therapy of standard chemotherapy and mTOR inhibitors might alleviate the pro-tumorigenic aspect of the senescence induction. Both studies show that mTOR inhibition suppresses the SASP but does not overcome the proliferative arrest. The reason for this is not clear, but, as both sets of authors speculate, the well-recognised anti-proliferative effects of mTOR inhibition and/or the heterogeneous nature of the SASP components might underlie these observations. Laberge et al. 2 showed that the co-administration of rapamycin and a chemotherapeutic drug to mice injected with a tumour cell line, with or without normal fibroblasts, elicited a better outcome than chemotherapy alone, in conditions where rapamycin alone has no benefit.
The discovery of the anti-SASP activity of mTOR inhibition is encouraging, especially considering that the anti-proliferative activity of mTOR inhibitors has already been exploited in clinical and preclinical studies in some types of cancer 4 . However, it is critical to consider both the cell-autonomous and non-cell-autonomous activities of senescence in order to achieve maximal benefits. The SASP is known to be tumour suppressive not only in preneoplastic tumours (represented by OIS) but also in established cancers, through anti-proliferative effects (Fig. 1a(ii,iii) ) and/or the activation of the immune surveillance of senescent cells (Fig. 1a(iv) ) 14, 15 . Although the current studies suggest that mTOR inhibition does not reverse the proliferative arrest, further investigation would be required to determine the stability of the arrest. Indeed, it was previously suggested that mTOR inhibition diverts senescence to quiescence 5 . mTOR activation triggers several negative feedback signals towards the PI3K pathway, which can be activated by mTOR inhibition 4 , providing a rationale for the use of inhibitors that block both mTOR and PI3K in cancer therapy. Similarly, such dual inhibitors would be useful to block the SASP and to reinforce senescence arrest. Using a mouse liver OIS model, in which the induction and immune-mediated elimination of OIS hepatocytes can be evaluated 
STIMATE reveals a STIM1 transitional state
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Decreases in endoplasmic reticulum calcium content are sensed by resident STIM proteins, which can activate plasma membrane Orai channels to facilitate Ca 2+ entry. The role of STIMATE, a previously unknown component of the store-operated calcium entry complex, has now been identified and defined. Figure 1 Regulation of STIM1 activation by STIMATE. When the ER is replete with Ca 2+ (left) resting STIM1 exists as a dimer with Ca 2+ bound to its luminal EF-hands and in a folded conformation with SOAR closely associated with CC1. STIMATE is located in the ER membrane, available to modulate STIM1 activation. As ER luminal Ca 2+ levels decrease (middle), Ca 2+ dissociates from the EF-hands of STIM, resulting in a conformational change that promotes binding between STIMATE and CC1. This relieves inhibition of SOAR, leading to transformation of STIM1 into its fully activated, unfolded conformation (right). STIM1 can then translocate to ER-PM junctions where it can facilitate SOCE. Inset, schematic of STIM1 domains: Poly-K, lysine-rich domain; SOAR, STIM Orai1-activating region; CC1, coiled-coil 1; TM, transmembrane domain; SAM, sterile α motif; cEF, canonical EF-hand; hEF, homologous EF-hand. 
